# United Therapeutics Drops 5.2% Despite BTIG Buy Rating

> United Therapeutics shares fell 5.2% Friday as BTIG upgraded to buy with $728 target.
- Title: United Therapeutics Drops 5.2% Despite BTIG Buy Rating
- Summary: United Therapeutics shares fell 5.2% Friday as BTIG upgraded to buy with $728 target. United Therapeutics dropped 5.2% Friday despite BTIG's buy rating and…
- Keywords: united therapeutics corporation, uthr, btig, price target, specialty pharmaceutical, market capitalization, United, Therapeutics, Drops, Despite, Buy, Rating
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/why-united-therapeutics-is-dropping-5-2-btig-upgrades-to-buy
- Author: AlphaStreet Newsdesk
- Published: 2026-10-02T19:31:51+00:00
- Read time: 1 min
- Topics: united therapeutics corporation, uthr, btig, price target, specialty pharmaceutical, market capitalization
## United Therapeutics Plunges
United Therapeutics Corporation plunged 5.2% on friday despite a bullish call from btig.
## BTIG Upgrades to Buy
btig issued a buy rating with a price target of $728 implying significant upside.
## Market Reaction
shares closed at $541.71 on heavy volume of 532,201 shares as market cap dropped.
## Volume Spike
the 532,201 shares changed hands indicate heightened activity as investors digest the analyst call.
## Investor Skepticism
investors may be skeptical of btig's $728 target or weighting other factors more heavily.
## What to Watch
investors should monitor stock support at current levels or if selling pressure persists next week.
## Key takeaway

United Therapeutics dropped 5.2% Friday despite BTIG's buy rating and $728 price target.